Bacillus of calmette and guerin vaccine, live Intradermal and Chloramphenicol Sodium Succinate
Determining the interaction of Bacillus of calmette and guerin vaccine, live Intradermal and Chloramphenicol Sodium Succinate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Antibiotics may interfere with the anti-tumor activity of intravesical BCG, which contains a live, attenuated strain of Mycobacterium bovis. Available data suggest that intravesical BCG may be sensitive to most antibiotics, particularly those that are routinely used in the treatment of tuberculosis such as streptomycin, para-aminosalicylic acid (PAS), isoniazid (INH), rifampin, and ethambutol. It is reportedly not sensitive to pyrazinamide or cycloserine. Regardless of clinical susceptibility data, however, most antibacterials may still interfere with BCG in the bladder due to their high urinary recovery. MANAGEMENT: Intravesical BCG should not be used in individuals with concurrent infections. For patients being treated with antibiotics, intravesical instillations of BCG should generally be postponed until completion of antibiotic therapy. If a bacterial urinary tract infection (UTI) occurs, therapy with intravesical BCG should be postponed or interrupted until complete resolution of the infection, not only because antimicrobial administration may diminish the anti-tumor efficacy of BCG, but also because the combination of a UTI and BCG-induced cystitis may lead to more severe adverse effects on the genitourinary tract. There are no data to suggest that the acute, local urinary tract toxicity common with intravesical administration of BCG is due to mycobacterial infection, thus antituberculosis drugs should not be used to prevent or treat the local, irritative toxicities of intravesical BCG. References Durek C, Rusch-Gerdes S, Jocham D, Bohle A "Interference of modern antibacterials with bacillus Calmette-Guerin viability." J Urol 162 (1999): 1959-62 Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Cerner Multum, Inc. "Australian Product Information." O 0 "Product Information. Tice BCG Live (for intravesical use) (BCG)." Organon Pharmaceuticals, West Orange, NJ. View all 4 references
Professional:GENERALLY AVOID: Antibiotics may interfere with the anti-tumor activity of intravesical BCG, which contains a live, attenuated strain of Mycobacterium bovis. Available data suggest that intravesical BCG may be sensitive to most antibiotics, particularly those that are routinely used in the treatment of tuberculosis such as streptomycin, para-aminosalicylic acid (PAS), isoniazid (INH), rifampin, and ethambutol. It is reportedly not sensitive to pyrazinamide or cycloserine. Regardless of clinical susceptibility data, however, most antibacterials may still interfere with BCG in the bladder due to their high urinary recovery.
MANAGEMENT: Intravesical BCG should not be used in individuals with concurrent infections. For patients being treated with antibiotics, intravesical instillations of BCG should generally be postponed until completion of antibiotic therapy. If a bacterial urinary tract infection (UTI) occurs, therapy with intravesical BCG should be postponed or interrupted until complete resolution of the infection, not only because antimicrobial administration may diminish the anti-tumor efficacy of BCG, but also because the combination of a UTI and BCG-induced cystitis may lead to more severe adverse effects on the genitourinary tract. There are no data to suggest that the acute, local urinary tract toxicity common with intravesical administration of BCG is due to mycobacterial infection, thus antituberculosis drugs should not be used to prevent or treat the local, irritative toxicities of intravesical BCG.
- Durek C, Rusch-Gerdes S, Jocham D, Bohle A "Interference of modern antibacterials with bacillus Calmette-Guerin viability." J Urol 162 (1999): 1959-62
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Tice BCG Live (for intravesical use) (BCG)." Organon Pharmaceuticals, West Orange, NJ.
Generic Name: bcg
Brand name: Tice BCG Live, Tice BCG Vaccine, Theracys 3, TheraCys, BCG vaccine, Tice BCG
Synonyms: BCG intravesical, BCG (Intravesical)
Generic Name: chloramphenicol
Brand name:
Synonyms: Chloramphenicol, Chloramphenicol (Systemic)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Bacillus of calmette and guerin vaccine, live Intradermal-Chloraseptic (Benzocaine and Menthol Lozenges)
- Bacillus of calmette and guerin vaccine, live Intradermal-Chloraseptic (Benzocaine and Menthol Strips)
- Bacillus of calmette and guerin vaccine, live Intradermal-Chloraseptic Kids
- Bacillus of calmette and guerin vaccine, live Intradermal-Chlorcyclizine and phenylephrine
- Bacillus of calmette and guerin vaccine, live Intradermal-Chlorcyclizine and pseudoephedrine
- Bacillus of calmette and guerin vaccine, live Intradermal-Chlorcyclizine and Pseudoephedrine Liquid
- Chloramphenicol Sodium Succinate-Bacillus of calmette and guerin vaccine, live Intravesical
- Chloramphenicol Sodium Succinate-Bacitracin (Systemic)
- Chloramphenicol Sodium Succinate-Bacitracin injection
- Chloramphenicol Sodium Succinate-Bacitracin, hydrocortisone, neomycin, and polymyxin B ophthalmic
- Chloramphenicol Sodium Succinate-Bacitracin, neomycin, and polymyxin B topical
- Chloramphenicol Sodium Succinate-Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (Ophthalmic)